Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]

Graham Rena (Lead / Corresponding author), Ify R. Mordi (Lead / Corresponding author), Chim C. Lang (Lead / Corresponding author)

Research output: Contribution to journalArticlepeer-review

Abstract

It has come to our attention that figure 1 of our recent article [1], is incorrect. The figure is presented correctly below and where the figure is referred to, the article text should read as follows: “In meta-analysis of recent CVOTs, consistent with a CV-protective effect of metformin, metformin use at baseline is associated with a lower risk of CV death (OR 0.69 95% CI 0.64–0.74), in both the placebo and active drug groups (interaction p value 0.77) (Figure 1)”. The Odds Ratio arising from the analysis is minimally affected by the error and the conclusions of the review unaffected. We apologise for this error. [Figure presented]

Original languageEnglish
Number of pages1
JournalCurrent Opinion in Pharmacology
DOIs
Publication statusE-pub ahead of print - 11 May 2021

Fingerprint Dive into the research topics of 'Corrigendum to "Metformin: Still the sweet spot for CV protection in diabetes?" [Curr Opin Pharmacol 54 (2020) 202-208]'. Together they form a unique fingerprint.

Cite this